Table 3.
Comparison of gene domains and clinical features of 31 cases with mutation-related epileptic encephalopathy.
| Domain involved | χ2 | P | ||||
|---|---|---|---|---|---|---|
| GTPase | Middle | |||||
| No. | Percent | No. | Percent | |||
| Sex | 0.285 | 0.5935 | ||||
| Female | 6 | 27.27% | 3 | 37.50% | ||
| Male | 16 | 72.73% | 5 | 62.50% | ||
| Age at seizure onset | 1.829 | 0.4007 | ||||
| <6 months | 9 | 42.86% | 6 | 66.67% | ||
| >12 months | 2 | 9.52% | 1 | 11.11% | ||
| 6–12 months | 10 | 47.62% | 2 | 22.22% | ||
| Seizure type at onset | 0.359 | 0.5491 | ||||
| IS/ES | 15 | 78.95% | 4 | 66.67% | ||
| Other type | 4 | 21.05% | 2 | 33.33% | ||
| Seizure outcome | — | 0.1145 | ||||
| Intractable | 20 | 95.24% | 4 | 66.67% | ||
| Seizure-free | 1 | 4.76% | 2 | 33.33% | ||
| ID | 0.353 | 0.5523 | ||||
| Profound | 13 | 59.09% | 5 | 71.43% | ||
| Severe | 9 | 40.91% | 2 | 28.57% | ||
IS, infantile spasms; ES, epileptic spasms; ID, intellectual disability.